CODX PE Ratio & Valuation, Is CODX Overvalued

Historical Valuation

Co-Diagnostics Inc (CODX) is now in the Fair zone, suggesting that its current forward PS ratio of 17.97 is considered Fairly compared with the five-year average of 5.84. The fair price of Co-Diagnostics Inc (CODX) is between 0.33 to 4.23 according to relative valuation method.

Relative Value

Fair Zone

0.33-4.23

Current Price：3.49

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Co-Diagnostics Inc (CODX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Co-Diagnostics Inc (CODX) has a current Price-to-Book (P/B) ratio of 0.22. Compared to its 3-year average P/B ratio of 0.40, the current P/B ratio is approximately -43.66% higher. Relative to its 5-year average P/B ratio of 1.05, the current P/B ratio is about -78.56% higher. Co-Diagnostics Inc (CODX) has a Forward Free Cash Flow (FCF) yield of approximately -281.87%. Compared to its 3-year average FCF yield of -112.72%, the current FCF yield is approximately 150.05% lower. Relative to its 5-year average FCF yield of -58.34%, the current FCF yield is about 383.18% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for CODX competitors is 4.56, providing a benchmark for relative valuation. Co-Diagnostics Inc Corp (CODX.O) exhibits a P/S ratio of 17.97, which is 294.38% above the industry average. Given its robust revenue growth of -77.32%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of CODX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of CODX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is CODX currently overvalued or undervalued?

What is Co-Diagnostics Inc (CODX) fair value?

CODX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Co-Diagnostics Inc (CODX) is between 0.33 to 4.23 according to relative valuation method.

How does CODX's valuation metrics compare to the industry average?

The average P/S ratio for CODX's competitors is 4.56, providing a benchmark for relative valuation. Co-Diagnostics Inc Corp (CODX) exhibits a P/S ratio of 17.97, which is 294.38% above the industry average. Given its robust revenue growth of -77.32%, this premium appears unsustainable.

What is the current P/B ratio for Co-Diagnostics Inc (CODX) as of Mar 11 2026?

As of Mar 11 2026, Co-Diagnostics Inc (CODX) has a P/B ratio of 0.22. This indicates that the market values CODX at 0.22 times its book value.

What is the current FCF Yield for Co-Diagnostics Inc (CODX) as of Mar 11 2026?

As of Mar 11 2026, Co-Diagnostics Inc (CODX) has a FCF Yield of -281.87%. This means that for every dollar of Co-Diagnostics Inc's market capitalization, the company generates -281.87 cents in free cash flow.

What is the current Forward P/E ratio for Co-Diagnostics Inc (CODX) as of Mar 11 2026?

As of Mar 11 2026, Co-Diagnostics Inc (CODX) has a Forward P/E ratio of -0.42. This means the market is willing to pay $-0.42 for every dollar of Co-Diagnostics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Co-Diagnostics Inc (CODX) as of Mar 11 2026?

As of Mar 11 2026, Co-Diagnostics Inc (CODX) has a Forward P/S ratio of 17.97. This means the market is valuing CODX at $17.97 for every dollar of expected revenue over the next 12 months.

CODX Valuation